272121-15-0
Chemical Structure
ATWLPPR Peptide
- CAS No.: 272121-15-0
- Formula:C40H61N11O9
- Molecular Weight:839.98
IUPAC Name: L-alanyl-L-threonyl-L-tryptophyl-L-leucyl-L-prolyl-L-prolyl-L-arginine
InChIKey: MKSPBYRGLCNGRC-OEMOKZHXSA-N
SMILES: O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](CC(C)C)C(N3[C@@H](CCC3)C(N4[C@@H](CCC4)C(N[C@@H](CCCNC(N)=N)C(O)=O)=O)=O)=O)=O)=O)[C@H](C)N
Biological Activity: ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ATWLPPR Peptide | 99.63% | ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.) | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
